Becker, R
Braun, U
Schwarz, A J
Gass, N
Schweiger, J I
Weber-Fahr, W
Schenker, E
Spedding, M
Clemm von Hohenberg, C
Risterucci, C
Zang, Z
Grimm, O
Tost, H
Sartorius, A
Meyer-Lindenberg, A
Article History
Received: 20 November 2015
Revised: 23 February 2016
Accepted: 28 February 2016
First Online: 19 April 2016
Competing interests
: AM-L received consultance fees from Astra Zeneca, Elsevier, F. Hoffmann-La Roche, Gerson Lehrman Group, Lund-beck foundation, Outcome Europe Sárl, Outcome Sciences, Roche Pharma, Servier International and Thieme Verlag, and lecture fees—including the travel fees—from Abbott, Astra Zeneca, Aula Médica Congresos, BASF, Groupo Ferrer International, Janssen-Cilag, Lilly Deutschland, LVR Klinikum Düsseldorf, Servier Deutschland, Otsuka Pharmaceuticals. AJS is an employee and shareholder of Eli Lilly. ES is a full-time employee of Servier. The remaining authors declare no conflict of interest.